Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Frederick L. Locke, Sattva S. Neelapu, Caron A. Jacobson et al.|The Lancet Oncology|2018

Cited by 2.3k